Long-term outcomes of young, node-negative, chemotherapy-naïve, triple-negative breast cancer patients according to BRCA1 status.
Yuwei WangGwen M H E DackusEfraim H RosenbergSten CornelissenLeonora W de BooAnnegien BroeksWim BrugmanTerry W S ChanPaul J van DiestMichael HauptmannNatalie D Ter HoeveOlga I IsaevaVincent M T de JongKatarzyna JóźwiakRoelof J C KluinMarleen KokEsther KoopPetra M NederlofMark OpdamPhilip C SchoutenSabine SieslingCharlaine van SteenisAdri C VoogdWillem VreulsRoberto F SalgadoSabine C LinnMarjanka K SchmidtPublished in: BMC medicine (2024)
Although both gBRCA1m and tumor BRCA1-PM alter BRCA1 gene transcription, they are associated with different outcomes in young, node-negative, chemotherapy-naïve TNBC patients. By combining sTILs and BRCA1 status for risk classification, we were able to identify potential subgroups in this population to intensify and optimize adjuvant treatment.